title: Clinical pharmacokinetics and delivery of bovine superoxide dismutase.
abstract: Experimentally, superoxide dismutase (SOD) protects against cytotoxological and histotoxological effects of superoxide anions, which play a fundamental role where inflammatory processes are involved. Currently, only bovine copper containing SOD (Cu-SOD) is available for clinical application in the treatment of patients with various arthritic diseases. The intramuscular route is the principal route to administer usual dosages of bovine Cu-SOD 4 to 32mg, 2 or 3 times weekly. A single dose corresponds to an optimal dose ranging from 30 to 200 micrograms/kg, determined from an established dose-response curve. After intramuscular injection of bovine Cu-SOD 8, 16 and 32mg the peak plasma concentration occurs 4 to 8 hours postdose and is 0.05, 0.16 and 0.39 mg/L, respectively. Clinically this metallo-protein is particularly effective for the treatment of inflammation and toxicity resulting from ionising irradiations, ischaemia and tumours. The major advantages of liposomally encapsulated bovine Cu-SOD are its improved pharmacokinetic characteristics, leading to a longer plasma half-life and a slower release of free bovine Cu-SOD. In humans, bovine Cu-SOD (free or liposomal), although a foreign protein, is well tolerated and produces no acute or delayed toxic effects.
authors.affiliation: Institut de Recherches Pharmacologiques, Faculté de Médecine, Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Jadot
authors.forename: A
authors.initials: A
authors.lastname: Vaille
authors.forename: J
authors.initials: J
authors.lastname: Maldonado
authors.forename: P
authors.initials: P
authors.lastname: Vanelle
mesh_terms: D000818:Animals; D001168:Arthritis / Q000188:drug therapy; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy; D002986:Clinical Trials as Topic; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D008081:Liposomes; D008297:Male; D010411:Penile Induration / Q000188:drug therapy; D011349:Proctitis / Q000188:drug therapy; D011878:Radiotherapy; D013482:Superoxide Dismutase / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology
chemical_list: D005609:Free Radicals; D008081:Liposomes; D013482:Superoxide Dismutase